Menu Search
Equities

Solventum Corp

KB7:MUN

Solventum Corp

Actions
  • Price (EUR)67.75
  • Today's Change1.50 / 2.26%
  • Shares traded3.00
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of Nov 22 2024 16:26 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Solventum Corp. is a global healthcare company. Its segments include Medical Surgical, Dental Solutions, Health Information Systems, and Purification and Filtration. Medical Surgical is a provider of solutions including advanced wound care, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes. Dental Solutions provides dental and orthodontic products include brackets, aligners, restorative cements, and bonding agents that span the life of the tooth, including products designed for preventative dental care, direct and indirect restoration, and broad orthodontic needs. Health Information Systems offers healthcare systems with software solutions, including computer-assisted physician documentation, direct-to-bill and coding automation, speech recognition, and data visualization platforms. Purification and Filtration is a provider of purification and filtration technologies including filters, purifiers, cartridges, and membranes.

  • Revenue in USD (TTM)8.22bn
  • Net income in USD720.00m
  • Incorporated2023
  • Employees22.01k
  • Location
    Solventum CorpC/O 3M Company3M Center, Building 275-6W-02ST. PAUL 55144-1000United StatesUSA
  • Phone+1 (651) 733-1110
  • Fax+1 (302) 636-5454
  • Websitehttps://www.solventum.com/en-us/home/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		SOLV:NYQ since
announced		Transaction
value
MediWound LtdRumoured06 Jul 202406 Jul 2024Rumoured41.90%--
Data delayed at least 15 minutes, as of Nov 22 2024 21:10 GMT.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.